Routine Cerebrospinal Fluid (CSF) Analysis

European Handbook of Neurological Management: Second Edition

Volumn 1, Issue , 2010, Pages 5-17

  Deisenhammer, F ^a   Bartos, A ^b   Egg, R ^a   Gilhus, N E ^c,h   Giovannoni, G ^d   Rauer, S ^e   Sellebjerg, F ^f   Tumani, H ^g  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF BERGEN   (Norway)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF FREIBURG   (Germany)

^f Mental Health Center Glostrup   (Denmark)

^g UNIVERSITY OF ULM   (Germany)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Blood CSF barrier, a physical barrier consisting of different anatomical structures; CSF glucose concentration CSF serum glucose ratio and lactate; CSF to serum albumin concentration quotient (Qalb) to evaluate blood CSF barrier integrity; CSF, an ultrafiltrate of plasma, containing immunoglobulins passively transferred from plasma; CSF, obtained with relative ease by lumbar puncture (LP); Detection of intrathecal oligoclonal IgG in CSF useful diagnostically; Intrathecal Ig synthesis, in mainly inflammatory CNS diseases; Quality assurance in CSF diagnostics; Quantitative analysis of total protein and albumin; Routine cerebrospinal fluid (CSF) analysis CSF, dynamic, metabolically active substance having many important functions

Indexed keywords

EID: 84885552085     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444328394.ch1     Document Type: Chapter

References (72)

1. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations 2004. Eur J Neurol 2004; 11: 577-81.
2. Thompson EJ. The CSF Proteins: A Biochemical Approach. Amsterdam, Netherlands: Elsevier, 1988.
3. Reiber H. Flow rate of cerebrospinal fiuid (CSF)-a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci 1994; 122: 189-203.
4. Eeg-Olofson O, Link H, Wigertz A. Concentrations of CSF proteins as a measure of blood brain barrier function and synthesis of IgG within the CNS in'normal'subjects from the age of 6 months to 30 years. Acta Paediatr Scand 1981; 70: 167-70.
5. Statz A, Felgenhauer K. Development of the blood-CSF barrier. Develop Med Child Neurol 1983; 25: 152-61.
6. Andersson M, Alvarez-Cermeño J, Bernadi G, et al. Cerebrospinal fiuid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994; 57: 897-902.
7. Blennow K, Fredman P, Wallin A, Gottfries C-G, L å ngstr öm G, Svennerholm L. Protein analyses in cerebrospinal fiuid. I. Infiuence of concentration gradients for proteins on cerebrospinal fiuid/serum albumin ratio. Eur Neurol 1993; 33: 126-8.
8. Reiber H. External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fiuid (CSF) proteins based on CSF/serum quotients. Clin Chem 1995; 41: 256-63.
9. Kornhuber J, Kaiserauer CH, Kornhuber AW, Kornhuber ME. Alcohol consumption and blood-cerebrospinal fiuid barrier dysfunction in man. Neurosci Lett 1987; 79: 218-22.
10. Skouen JS, Larsen JL, Vollset SE. Cerebrospinal fiuid protein concentrations related to clinical findings in patients with sciatica caused by disk herniation. J Spinal Disord 1994; 7: 12-8.
11. Nyström E, Hamberger A, Lindstedt G, Lundquist C, Wikkelsö C. Cerebrospinal fiuid proteins in subclinical and overt hypothyroidism. Acta Neurol Scand 1997; 95: 311-4.
12. Seyfert S, Kunzmann V, Schwertfeger N, Koch HC, Faulstich A. Determinants of lumbar CSF protein concentration. J Neurol 2002; 249: 1021-6.
13. Stockstill MT, Kauffman CA. Comparison of cryptococcal and tuberculous meningitis. Arch Neurol 1983; 40: 81-5.
14. Kaiser R. Neuroborreliosis. J Neurol 1998; 245: 247-55.
15. Negrini B, Kelleher KJ, Wald ER. Cerebrospinal fiuid findings in aseptic versus bacterial meningitis. Pediatrics 2000; 105: 316-9.
16. Lindquist L, Linne T, Hansson LO, Kalin M, Axelsson G. Value of cerebrospinal fiuid analysis in the differential diagnosis of meningitis: a study in 710 patients with suspected central nervous system infection. Eur J Clin Microbiol Infect Dis 1988; 7: 374-80.
17. Koskiniemi M, Vaheri A, Taskinen E. Cerebrospinal fiuid alterations in herpes simplex virus encephalitis. Rev Infect Dis 1984; 6: 608-18.
18. Jerrard DA, Hanna JR, Schindelheim GL. Cerebrospinal fiuid. J Emerg Med 2001; 21: 171-8.
19. Segurado OG, Kruger H, Mertens HG. Clinical significance of serum and CSF findings in the Guillain-Barre syndrome and related disorders. J Neurol 1986; 233: 202-8.
20. Twijnstra A, Ongerboer de Visser BW, van Zanten AP, Hart AA, Nooyen WJ. Serial lumbar and ventricular cerebrospinal fiuid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol 1989; 7: 57-63.
21. Bruna J, González L, Miró J, Velasco R, Gil M, Tortosa A. Neuro-Oncology Unit of the Institute of Biomedical Investigation of Bellvitge. Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fiuid features. Cancer 2009; 115: 381-9.
22. Brettschneider J, Claus A, Kassubek J, Tumani H. Isolated blood-cerebrospinal fiuid barrier dysfunction: prevalence and associated diseases. J Neurol 2005; 252: 1067-73.
23. Delpech B, Lichtblau E. Étude quantitative des immunoglobulines G et de l'albumine du liquide cephalo rachidien. Clin Chim Acta 1972; 37: 15-23.
24. Ganrot K, Laurell C-B. Measurement of IgG and albumin content of cerebrospinal fiuid, and its interpretation. Clin Chem 1974; 20: 571-3.
25. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977; 37: 397-401.
26. Schipper HI, Bardosi A, Jacobi C, Felgenhauer K. Meningeal carcinomatosis: origin of local IgG production in the CSF. Neurology 1988; 38: 413-6.
27. McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fiuid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 1990; 113: 1269-89.
28. Öhman S, Ernerudh J, Forsberg P, Henriksson A, von Schenck H, Vrethem M. Comparison of seven formulae and isoelectrofocusing for determination of intrathecally produced IgG in neurological diseases. Ann Clin Biochem 1992; 29: 405-10.
29. Sellebjerg F, Christiansen M, Rasmussen LS, Jaliachvili I, Nielsen PM, Frederiksen JL. The cerebrospinal fiuid in multiple sclerosis. Quantitative assessment of intrathecal immunoglobulin synthesis by empirical formulae. Eur J Neurol 1996; 3: 548-59.
30. Korenke GC, Reiber H, Hunneman DH, Hanefeld F. Intrathecal IgA synthesis in X-linked cerebral adrenoleukocystrophy. J Child Neurol 1997; 12: 314-20.
31. Felgenhauer K. Differentiation of the humoral immune response in infiammatory diseases of the central nervous system. J Neurol 1982; 228: 223-37.
32. Felgenhauer K, Schädlich H-J. The compartmental IgM and IgA response within the central nervous system. J Neurol Sci 1987; 77: 125-35.
33. Sharief MK, Keir G, Thompson EJ. Intrathecal synthesis of IgM in neurological diseases: a comparison between detection of oligoclonal bands and quantitative estimation. J Neurol Sci 1990; 96: 131-43.
34. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
35. Rauer S, Kaiser R. Demonstration of anti-HuD specific oligoclonal bands in the cerebrospinal fiuid from patients with paraneoplastic neurological syndromes. Qualitative evidence of anti-HuD specific IgG-synthesis in the central nervous system. J Neuroimmunol 2000; 111: 241-4.
36. Stich O, Graus F, Rasiah C, Rauer S. Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol 2003; 141: 165-9.
37. Storstein A, Monstad SE, Honnorat J, Vedeler CA. Paraneoplastic antibodies detected by isoelectric focusing of cerebrospinal fiuid and serum. J Neuroimmunol 2004; 155: 150-4.
38. Keir G, Luxton RW, Thompson EJ. Isoelectric focusing of cerebrospinal fiuid immunoglobulin G: an annotated update. Ann Clin Biochem 1990; 27: 436-43.
39. Blennow K, Fredman P. Detection of cerebrospinal fiuid leakage by isoelectric focusing on polyacrylamide gels with silver staining using the PhastSystem. Acta Neurochir 1995; 136: 135-9.
40. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fiuid analysis in the diagnosis of multiple sclerosis. Arch Neurol 2005; 62: 865-70.
41. Poser CM, Paty W, Scheinberg LC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
42. Schumacher FA, Beebe GW, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965; 122: 552-68.
43. Feigin RD, McCracken GH Jr, Klein JO. Diagnosis and management of meningitis. Pediatr Infect Dis J 1992; 11: 785-814.
44. Watson MA, Scott MG. Clinical utility of biochemical analysis of cerebrospinal fiuid. Clin Chem 1995; 41: 343-60.
45. Steele RW, Marmer DJ, O'Brien MD, Tyson ST, Steele CR. Leukocyte survival in cerebrospinal fiuid. J Clin Microbiol 1986; 23: 965-6.
46. Lamers KJB, Wevers RA. Cerebrospinal fiuid diagnostics: biochemical and clinical aspects. Klin Biochem Metab 1995; 3: 63-75.
47. Roma AA, Garcia A, Avagnina A, Rescia C, Elsner B. Lymphoid and myeloid neoplasms involving cerebrospinal fiuid: comparison of morphologic examination and immunophenotyping by fiow cytometry. Diagn Cytopathol 2002; 27: 271-5.
48. Adam P, Taborsky L, Sobek O, et al. Cerebrospinal fiuid. Adv Clin Chem 2001; 36: 1-62.
49. Spanos A, Harrell FE Jr, Durack DT. Differential diagnosis of acute meningitis. An analysis of the predictive value of initial observations. JAMA 1989; 262: 2700-7.
50. Zeman D, Adam P, Kalistova H, Sobek O, Andel J, Andel M. Cerebrospinal fiuid cytologic findings in multiple sclerosis. A comparison between patient subgroups. Acta Cytol 2001; 45: 51-9.
51. UK National External Quality Assessment Scheme for Immunochemistry Working Group. National guidelines for analysis of cerebrospinal fiuid for bilirubin in suspected subarachnoid haemorrhage. Ann Clin Biochem 2003; 40: 481-8.
52. Twijnstra A, Ongerboer de Visser BW, van Zanten AP. Diagnosis of leptomeningeal metastasis. Clin Neurol Neurosurg 1987; 89: 79-85.
53. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fiuid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82: 733-9.
54. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49: 759-72.
55. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990; 9: 225-9.
56. Schlossberg D. Infections of the Nervous System. Berlin: Springer-Verlag, 1990.
57. Kaiser R. Entzündliche und infektiöse Erkrankungen. In: Hufschmidt A, L ü cking CH (eds) Neurologie Compact, Leitlinie F ü r Klinik Und Praxis. Stuttgart: Georg Thieme Verlag, 2002; pp. 121-172.
58. Takahashi T, Nakayama T, Tamura M, et al. Nested polymerase chain reaction for assessing the clinical course of tuberculous meningitis. Neurology 2005; 64: 1789-93.
59. Jeffery KJ, Read SJ, Peto TE, Mayon-White RT, Bangham CR. Diagnosis of viral infections of the central nervous system: clinical interpretation of PCR results. Lancet 1997; 349: 313-7.
60. Davies NW, Brown LJ, Gonde J, et al. Factors infiuencing PCR detection of viruses in cerebrospinal fiuid of patients with suspected CNS infections. J Neurol Neurosurg Psychiatry 2005; 76: 82-7.
61. Kennedy PG. Viral encephalitis. J Neurol 2005; 252: 268-72.
62. Reiber H, Thompson EJ, Grimsley G, et al. Quality assurance for cerebrospinal fiuid protein analysis: international consensus by an internet-based group discussion. Clin Chem Lab Med 2003; 41: 331-7. Available at: www.teamspace.net/CSF.
63. Linke E, Wieczorek V, Zimmermann K. Qualitätskontrolle in der Liquorzytodiagnostik. In: Zettl UK, Lehmitz R, Mix E (eds) Klinische Liquordiagnostik, 2nd edn. Berlin/New York: Walter de Gruyter, 2005; pp. 380-91.
64. Petzold A, Altintas A, Andreonie L, et al. Neurofilament ELISA validation. J Immunol Methods 2009; Oct 24. 352: 23-31; [Epub ahead of print] doi:10.1016/j.jim.2009.09.014.
65. Fishman RA. Cerebrospinal Fluid in Diseases of the Nervous System. Philadelphia, PA: W.B. Saunders, 1992.
66. Jordan GW, Statland B, Halsted C. CSF lactate in diseases of the CNS. Arch Intern Med 1983; 143: 85-7.
67. Kniehl ER, Dörries HK, Geiss B, et al. In: Mauch H, L ü tticken R (eds) MiQ 17: Qualit ä tsstandards in Der Mikrobiologisch-Infektiologischen Diagnostik. München, Jena: Urban & Fischer, 2001; pp. 1-77.
68. Lo Re V 3rd, Gluckman SJ. Eosinophilic meningitis. A m J Med 2003; 114: 217-23.
69. Öhman S, Forsberg P, Nelson N, Vrethem M. An improved formula for the judgement of intrathecally produced IgG in the presence of blood brain barrier damage. Clin Chim Acta 1989; 181: 265-72.
70. Öhman S, Ernerudh J, Forsberg P, von Schenck H, Vrethem M. Improved formulae for the judgement of intrathecally produced IgA and IgM in the presence of blood CSF barrier damage. Ann Clin Biochem 1993; 30: 454-62.
71. Sabetta JR, Andriole VT. Cryptococcal infection of the central nervous system. Med Clin North Am 1985; 69: 333-44.
72. Seneviratne U. Guillain-Barr é syndrome. Postgrad Med J 2000; 76: 774-82.